https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — Alzheimer’s patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to…
